PeptidesInfo

Research area

Peptide safety

Safety evidence is only as good as the studies that collect it. Approved peptides have labelled adverse-event profiles from thousands of trial participants. Unapproved peptides sold online have almost none — and the products themselves may not contain what the label says. Absence of reported harm is not evidence of safety.

Abstract illustration of a peptide chain used as the peptide safety research hub image

Evidence map: peptides studied in this area

How grades work →
PeptideEvidence for this areaRegulatory statusWhat has been studied
SemaglutideEstablished evidenceFDA-approved for this useWell-characterised profile — GI effects most common; boxed warning for thyroid C-cell tumours (rodent finding); pancreatitis, gallbladder disease, and rare ileus reported.
TirzepatideEstablished evidenceFDA-approved for this useSimilar GI-dominant profile and boxed thyroid warning; large trial safety database.
TesamorelinEstablished evidenceFDA-approved for this useInjection-site reactions, arthralgia, fluid retention; contraindicated in active malignancy and pregnancy; IGF-1 monitoring recommended in label.
PT-141Established evidenceFDA-approved for this useNausea (~40%), flushing, injection-site reactions, transient blood-pressure rise, focal hyperpigmentation with frequent use.
Collagen peptidesEstablished evidenceNot FDA-approvedFood-grade protein hydrolysate; GRAS status; adverse events in trials are rare and mild (GI, taste).
CJC-1295Preliminary evidenceNot FDA-approvedShort human studies report headache, flushing, injection-site reactions; a death occurred in one early trial (deemed unrelated by investigators, but the programme was halted). Long-term GH/IGF-1 elevation risks unstudied.
IpamorelinPreliminary evidenceNot FDA-approvedEarly-phase human data only; a post-operative ileus programme was discontinued for lack of efficacy, not safety.
GHK-CuPreliminary evidenceNot FDA-approvedTopical use generally well tolerated in small trials; injectable use has no human safety data.
BPC-157Preclinical evidenceNot FDA-approvedOne small published human safety dataset; otherwise animal toxicology only. Long-term human safety unknown.
TB-500Preclinical evidenceNot FDA-approvedPhase 1/2 thymosin beta-4 trials report tolerability; the TB-500 fragment has no human safety data.

Grades reflect the strength of evidence for this research area specifically. Definitions: Established, Promising, Preliminary, Preclinical, Unsupported, Conflicting.

Two different kinds of "safe"

When a drug label lists side effects, that is evidence of systematic safety monitoring in thousands of people. When a vendor page says a research peptide "has no known side effects", that usually means no one has run the studies that would find them. The evidence grades on this page reflect how much is known, not how dangerous a compound is: an established grade means the safety profile is well characterised, which can include serious warnings.

What approved-peptide labels tell us

The GLP-1 and GIP/GLP-1 drugs carry boxed warnings for thyroid C-cell tumours based on rodent findings, and list gastrointestinal effects, pancreatitis, gallbladder disease and hypoglycaemia (with insulin or sulfonylureas) among their risks. Tesamorelin's label flags glucose intolerance, fluid retention and the need to monitor IGF-1. Bremelanotide's label warns of transient blood-pressure increases and skin hyperpigmentation. These are not reasons to avoid the drugs — they are what informed use looks like.

The unapproved-peptide problem is double

For BPC-157, TB-500, CJC-1295, ipamorelin and injectable GHK-Cu, two uncertainties stack:

  1. The molecule: little or no controlled human safety data, so long-term effects, drug interactions and rare harms are unknown.
  2. The product: "research use only" vials are not made under pharmaceutical quality standards. Independent testing of such products has found under-dosing, mislabelling and contamination — see our analysis of certificates of analysis. The FDA placed several of these peptides in category 2 of its compounding interim policies, citing possible immunogenicity and peptide-impurity concerns; most of those nominations have since been withdrawn by the nominators, which removes the listing without establishing that the substances are safe.

What we would need to see

Registered trials with prespecified safety monitoring, published in full, in the actual product formulations people are using. Until then, "no reported side effects" should be read as "no reporting".

Analyses in peptide safety

Safety4 min read

Counterfeit and Fake GLP-1 Products: How to Spot Them

Fake and counterfeit versions of semaglutide and tirzepatide are being sold online, sometimes with made-up pharmacy labels. Here is how the FDA says to recognize them and buy safely.

Regulation4 min read

Compounded Semaglutide: What the FDA Actually Says

Compounded semaglutide is not the same as Ozempic or Wegovy. It is not FDA-checked, the shortage that made it common is over, and the FDA has linked it to dosing errors and hospital visits. Here is the plain version.

Benefits5 min read

Peptides for Recovery: Which Benefits Are Actually Documented

Recovery is the most-marketed peptide benefit and the least proven. This separates the recovery claims with human trials behind them from the ones resting entirely on rodent studies — and names what would change the verdict.

Research analysis5 min read

GLP-1 Peptides: Established Uses Versus Emerging Research

Semaglutide and tirzepatide are the best-evidenced peptides in medicine — for specific uses. We separate the approved indications with large trials from the emerging research (kidney, liver, heart failure, sleep apnoea, Alzheimer's) and the open questions about regain, muscle loss and compounded products.

Research analysis6 min read

BPC-157: Human Evidence, Animal Research, and Open Questions

BPC-157 has hundreds of positive animal studies and almost no controlled human data. We separate what the rat research shows, what the few human reports show, what the FDA has said, and what would have to happen for the evidence grade to change.

Safety5 min read

Peptide Purity, Contamination, and the Limits of a Certificate of Analysis

A certificate of analysis is the main reassurance offered by 'research peptide' vendors. Here is what a CoA can and cannot tell you — identity, purity, quantity, sterility, endotoxin — why '99% pure' is not what it sounds like, and what independent testing of grey-market peptides has found.

Research analysis5 min read

CJC-1295 and Ipamorelin: Growth Hormone Research and Unanswered Risks

The 'CJC/ipa' stack is sold for muscle, fat loss, sleep and anti-aging. The human evidence is a handful of short hormone-level studies, two abandoned development programmes, and no outcome trials — plus a set of risks that have never been studied because the trials were never run.

Research analysis4 min read

Tesamorelin: Approved Use, Off-Label Interest, and Clinical Evidence

Tesamorelin is the one GHRH analogue that finished phase 3 and won FDA approval — for excess abdominal fat in HIV-associated lipodystrophy. We separate that established evidence from the off-label uses it is now marketed for: general visceral fat, liver fat, and cognition.

Research analysis4 min read

TB-500 and Thymosin Beta-4: What the Research Actually Studies

TB-500 is sold on the back of thymosin beta-4 research — a different molecule with real but early human trials in wounds and eye disease. We untangle which studies are about what, and what that means for the fragment people actually buy.

Research analysis4 min read

PT-141: Mechanism, Approved Use, Benefits, and Limitations

PT-141 (bremelanotide) is FDA-approved as Vyleesi for low sexual desire in premenopausal women, with modest benefits and a lot of nausea. Its use in men — the way it is mostly marketed online — was abandoned in development. Here is what the trials actually showed.

Research analysis4 min read

GHK-Cu: Skin, Hair, Wound Healing, and Evidence Quality

Copper peptide GHK-Cu has decades of laboratory work, small human trials for topical skin use, and a growing injectable market with no human data. We grade each claim — skin, hair, wounds, 'gene resetting' — separately.

Regulation6 min read

FDA-Approved, Off-Label, Investigational, and Unapproved Peptides

The regulatory status of a peptide is a fact about a decision, not a verdict on the evidence. This guide explains the four categories, what compounding rules changed in 2023–2025, and where every peptide we cover currently sits.

Foundations5 min read

How to Read Peptide Research Without Falling for Marketing

Most misleading peptide claims cite real studies. This guide shows how to tell a rat model from a human trial, a mechanism from an outcome, and a case report from evidence — with worked examples from BPC-157, growth hormone secretagogues and collagen research.